In a recent study published in Nature Biotechnology,1 Nahmad and colleagues reported in vivo B-cell engineering to generate broadly neutralizing antibodies(bnAbs)against human immunodeficiency virus type 1(HIV-1)in mi...In a recent study published in Nature Biotechnology,1 Nahmad and colleagues reported in vivo B-cell engineering to generate broadly neutralizing antibodies(bnAbs)against human immunodeficiency virus type 1(HIV-1)in mice.This proof-of-concept study suggests the possibility of in vivo B-cell engineering as a novel preventive or therapeutic approach against HIV-1 infection.展开更多
The epidemic of human immunodeficiency virus type 1(HIV-1)remains amajor threat to global public health,with approximately 38 million people living with HIV-1 worldwide.However,a prophylactic vaccine against HIV-1 is ...The epidemic of human immunodeficiency virus type 1(HIV-1)remains amajor threat to global public health,with approximately 38 million people living with HIV-1 worldwide.However,a prophylactic vaccine against HIV-1 is not available yet.In a recent study,1 Leggat and colleagues reported the first-in-human test of a germline-targeting HIV-1 vaccine candidate,eOD-GT860-mer adjuvanted with AS01B.Encouragingly,this strategy effectively activated the B cell precursors(germlines)of VRC01-class broadly neutralizing antibodies(bnAbs)in 97%(35 of 36)of vaccine recipients.展开更多
基金This work was supported by the National Natural Science Foundation of China(82271786,81971927)the Science and Technology Planning Project of Shenzhen City(20190804095916056,JCYJ20200109142601702)Youth Program of Chinese Academy of Sciences(E1BDEDF7241).
文摘In a recent study published in Nature Biotechnology,1 Nahmad and colleagues reported in vivo B-cell engineering to generate broadly neutralizing antibodies(bnAbs)against human immunodeficiency virus type 1(HIV-1)in mice.This proof-of-concept study suggests the possibility of in vivo B-cell engineering as a novel preventive or therapeutic approach against HIV-1 infection.
基金supported by the National Natural Science Foundation of China(81971927,82271786,and 32200765)the Science and Technology Planning Project of Shenzhen City(JCYJ20200109142601702 and 20190804095916056)Youth Program of Chinese Academy of Sciences(E1BDEDF7241).
文摘The epidemic of human immunodeficiency virus type 1(HIV-1)remains amajor threat to global public health,with approximately 38 million people living with HIV-1 worldwide.However,a prophylactic vaccine against HIV-1 is not available yet.In a recent study,1 Leggat and colleagues reported the first-in-human test of a germline-targeting HIV-1 vaccine candidate,eOD-GT860-mer adjuvanted with AS01B.Encouragingly,this strategy effectively activated the B cell precursors(germlines)of VRC01-class broadly neutralizing antibodies(bnAbs)in 97%(35 of 36)of vaccine recipients.
